A prospective observational study to evaluate the clinical outcomes and burden of disease of PD patients with motor fluctuations not adequately controlled by current PD medications (PROSPECT)

Study identification

• EU PAS number:
  EUPAS36303
• Study ID:
  40298
• Official title and acronym:
  A prospective observational study to evaluate the clinical outcomes and burden of disease of PD patients with motor fluctuations not adequately controlled by current PD medications (PROSPECT)
• DARWIN EU® study:
  No
• Study countries:
  Australia

  Canada

  France

  Japan

  Spain

  United Kingdom

  United States
• Study description:
  This is a prospective, multi-country, observational study evaluating the disease progression of advanced Parkinson's Disease (PD) patients experiencing motor fluctuations not adequately controlled by current PD medications.
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Planned:16/04/2020

Actual:16/04/2020

Study start date

Planned:30/09/2020

Actual:17/11/2020

Date of final study report

Planned:30/07/2024

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AbbVie

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

H20-012